Micron Biomedical Company Profile

Background

Micron Biomedical, founded in 2014 and headquartered in Atlanta, Georgia, is a clinical-stage life sciences company specializing in the development of dissolvable microarray-based technologies for needle-free drug and vaccine delivery. The company's mission is to radically expand access to treatments and vaccines, thereby improving global health outcomes. By eliminating the need for traditional injections, Micron aims to simplify drug administration, enhance patient compliance, and address logistical challenges associated with cold chain storage and medical waste.

Key Strategic Focus

Micron Biomedical's strategic focus centers on the commercialization of its proprietary Micro Array Patch (MAP) technology, designed for self-administration and caregiver administration of drugs and vaccines without needles. This technology targets a wide range of compounds, including nucleic acids, peptides, proteins, viruses (both inactivated and live-attenuated), and small-molecule drugs. The company aims to enhance the efficacy of drugs and vaccines, simplify storage and distribution, and improve patient compliance by offering a painless, easy-to-use alternative to traditional injections.

Financials and Funding

Since its inception, Micron Biomedical has secured significant funding to support its research and development activities:

Series A Financing: In November 2022, the company raised $14 million in a Series A financing round led by Global Health Investment Corporation (GHIC) and LTS Lohmann, with participation from GRA Venture Fund.

Series A Extension: In May 2023, Micron secured an additional $3 million investment from J2 Ventures, bringing the total Series A funding to $17 million.

Series A3 Financing: In January 2025, the company announced a $16 million extension round led by J2 Ventures and GHIC, bringing the total Series A equity raise to over $33 million.

Grant Support: Micron has received substantial non-dilutive funding, including a $7.5 million grant from the Bill & Melinda Gates Foundation in January 2025, totaling $43 million in support from the organization to date.

These funds are intended to advance the development and commercialization of Micron's needle-free drug and vaccine delivery technologies.

Pipeline Development

Micron Biomedical's pipeline includes several key projects:

Measles-Rubella (MR) Vaccine: The company is developing a needle-free version of the MR vaccine using its microarray technology. A Phase 1/2 clinical trial demonstrated safety, immunogenicity, and acceptability in children as young as nine months old. A $7.5 million grant from the Bill & Melinda Gates Foundation is supporting manufacturing scale-up and a Phase 2 trial in infants.

mRNA-Based Influenza Vaccine: In collaboration with Zipcode Bio, Micron is co-developing a needle-free, mRNA-based, broadly protective influenza vaccine. The project received a $2 million award from the Biomedical Advanced Research and Development Authority (BARDA) in January 2025.

Disease X Vaccines: Micron is working on needle-free vaccines against emerging infectious diseases, referred to as Disease X, supported by a $3.7 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI).

Technological Platform and Innovation

Micron Biomedical's proprietary technology is based on dissolvable microarrays designed for painless, needle-free delivery of vaccines and therapeutics. Key features include:

Proprietary Technologies: The microarray technology allows for the incorporation of various compounds, including nucleic acids, peptides, proteins, and viruses, into a dissolvable matrix that can be applied to the skin.

Scientific Methodologies: The technology enables rapid delivery of pharmaceuticals by applying the microarray to the skin and pressing a button, facilitating self-administration or administration by caregivers. The microarrays are thermostable, reducing or eliminating the need for cold chain storage.

Leadership Team

Micron Biomedical's leadership team comprises experienced professionals with diverse backgrounds:

Steven Damon, CEO: Over 25 years of experience in the medical device and pharmaceutical industries, including roles in M&A, business development, and commercial development.

Devin McAllister, PhD, EVP, Chief Technology Officer, Co-founder: 25 years of experience in medical devices and pharmaceutical dosage forms, including microneedle-based technologies.

Idean Marvasty, EVP, Chief Financial Officer: Over 15 years of experience in life sciences, having raised over $270 million in institutional financing.

Sebastien Henry, MS, MBA, EVP, Head of Technical Operations, Co-founder: Over 20 years of experience in microneedle and medical device fields, including product development responsibilities at Porex Surgical.

Leadership Changes

In September 2024, Dr. Sandeep Patel, former Director of BARDA's Division of Research, Innovation, and Ventures (DRIVe), joined Micron Biomedical's Board of Advisors to support the commercialization of the company's needle-free technology.